posit quarter guidanc
ep con re-affirmed
suggest gadvair approv immin spoke posit
sign stabil north america rais pt
higher ebitda remain ew
call commentari encourag number front
management indic one top eight top
gross margin product north america manufactur troubl
expect signific new product launch site
howev note exclud expens relat
restructuring/remedi program
management impli gadvair approv immin
convey base latest updat agenc
final stage label review note model
north america prospect better yoy top-lin declin suggest
north america segment revenu declin part due exit
low margin unprofit product addit management state
segment benefit new product launch broader set dosag
form beyond oral solid ytd launch
inject final management indic see stabil
bump estim pt adjust estim
follow revenue ebitda
ep
base revis estim rais pt ev/old
ebitda ev/new ebitda
summari revenu con ebitda
 unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
con ep con
ep upsid vs model includ
share count i/ yoy growth nutshel rev gross profit
revenu highlight north america revenu
europ rev row
rev rev
re-affirmed guidanc note strateg updat revenu guidanc
midpoint unch con ebitda guidanc
midpoint unch con ep guidanc
midpoint unch con manag
provid strateg updat review on-going estim
varianc section result vs ms consensu expect
pt base ebitda target multipl within
rang project ebitda compound-annual-growth-rate
ep compound-annual-growth-rate
ev/ebitda bull case ebitda
ev/ebitda bull case
ebitda
gener trend surpris upsid boost prospect new pipelin
driver moder us price pressur drive ebitda forecast
management pursu value-cr deal ev/ebitda increas
ev/ebitda base case ebitda
ev/ebitda base case ebitda
deliv modest growth ex-u segment growth offset pressur
us launch gadvair north american gener declin due
competit pressur morgantown facil manufactur challeng ex-
us segment continu deliv yoy growth
ev/ebitda bear case
ev/ebitda bear case ebitda
ebitda
gener busi wors model due sever competit
pressur morgantown facil issu key new launch delay
price pressur moder expect morgantown facil issu
problemat disclos date gadvair grestasi
launch delay ebitda forecast ev/ebitda multipl
contract
rate equal-weight see
earn uncertainti balanc rel
revenu ebitda ep
low convict
expect garner approv
gadvair grestasi
gener industri myl-specif gener
gadvair grestasi
gcopaxon uptak competit
epipen trend competit
financi result guidanc updat
fda action new product applic
success new product launch
resolut investig litig
risk achiev price
us gener environ may
deterior due competit pressur
facil issu could problemat
due approv delay and/or increas
may result fine claim
ex-u busi may fall short
per share equat approxim pre-tax
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
